Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis and Medicines for Malaria Venture (MMV) have entered into a three-year research agreement for malaria treatments.
Subscribe to our email newsletter
Under the agreement, both the parties will jointly work for identifying, characterizing and optimizing new treatments for malaria.
The ‘Orthology Malaria’ project aims at developing drug candidates from a set of Sanofi-aventis‘ compounds that have been selected for their potential activity against malaria parasites.
Each stage of the project will be investigated by the Sanofi-aventis/MMV joint steering committee and assessed according to MMV’s criteria for compound progression.
Sanofi-aventis Global Research & Development president Elias Zerhouni said this new partnership will enable them to mobilize each organization’s expertise, resources and know-how to identify novel medicines for malaria patients.